Literature DB >> 22890694

Smell in cystic fibrosis.

J Lindig1, C Steger, N Beiersdorf, R Michl, J F Beck, T Hummel, J G Mainz.   

Abstract

In cystic fibrosis (CF), the most frequent life threatening inherited disease in Caucasians, sinonasal mucosa is regularly affected by defective mucociliary clearance. This facilitates pathogen colonization into CF airways and causes frequent symptoms of rhinosinusitis, including an impaired sense of smell. Despite probable effects on nutrition and overall health, CF-rhinosinusitis is little understood: CF-associated smelling deficiencies reported in literature vary between 12 and 71 %. The aim of this study was to assess olfactory and gustatory function in relation to sinonasal symptoms and sinonasal colonization, and lung function and nutrition. Thirty-five CF patients of different ages were compared to 35 age-matched healthy controls. Olfactory function was assessed by 'Sniffin'Sticks', gustatory qualities by "Taste-strips", and symptoms by sino-nasal outcome test 20 (SNOT-20). Normosmia was found in 62.8 % of healthy controls but only in 28.6 % of CF patients. In contrast the majority of CF patients exhibited a smell loss; almost 62.9 % of them were hyposmic, and 8.6 % functionally anosmic. Importantly, reduced olfactory function only affected odor thresholds, which were significantly increased in CF, not odor identification. This suggests that the olfactory dysfunction in CF results from the olfactory periphery due to either problems in conduction and/or a functional lesion due to the inflammatory process. SNOT-20 scores increased continuously from normosmic to hyposmic and anosmic CF patients (means 7.2/11.1/28.3 points). Neither sinonasal pathogen colonization, gender, pulmonary function, nor allergy or sinonasal surgery appeared to have significant effects on olfactory function and taste. Olfactory disorders are considerably more frequent in CF patients than in age-matched healthy controls. Assessing these parameters within CF-routine care should be considered because of their importance to nutrition and, thus, overall therapy outcome.

Entities:  

Mesh:

Year:  2012        PMID: 22890694     DOI: 10.1007/s00405-012-2124-2

Source DB:  PubMed          Journal:  Eur Arch Otorhinolaryngol        ISSN: 0937-4477            Impact factor:   2.503


  29 in total

1.  Mometasone furoate nasal spray improves olfactory performance in seasonal allergic rhinitis.

Authors:  B A Stuck; A Blum; A E Hagner; T Hummel; L Klimek; K Hörmann
Journal:  Allergy       Date:  2003-11       Impact factor: 13.146

2.  Pulmonary function and clinical course in patients with cystic fibrosis after pulmonary colonization with Pseudomonas aeruginosa.

Authors:  E Kerem; M Corey; R Gold; H Levison
Journal:  J Pediatr       Date:  1990-05       Impact factor: 4.406

3.  [Do blind persons have a better sense of smell than normal sighted people?].

Authors:  Oliver Schwenn; Inga Hundorf; Bertram Moll; Susanne Pitz; Wolf J Mann
Journal:  Klin Monbl Augenheilkd       Date:  2002-09       Impact factor: 0.700

4.  Cognitive factors in odor detection, odor discrimination, and odor identification tasks.

Authors:  Margareta Hedner; Maria Larsson; Nancy Arnold; Gesualdo M Zucco; Thomas Hummel
Journal:  J Clin Exp Neuropsychol       Date:  2010-04-30       Impact factor: 2.475

Review 5.  Sinonasal disease in cystic fibrosis: clinical characteristics, diagnosis, and management.

Authors:  C Gysin; G A Alothman; B C Papsin
Journal:  Pediatr Pulmonol       Date:  2000-12

6.  "Sniffin' sticks": screening of olfactory performance.

Authors:  G Kobal; T Hummel; B Sekinger; S Barz; S Roscher; S Wolf
Journal:  Rhinology       Date:  1996-12       Impact factor: 3.681

7.  Multicenter investigation of 1,036 subjects using a standardized method for the assessment of olfactory function combining tests of odor identification, odor discrimination, and olfactory thresholds.

Authors:  G Kobal; L Klimek; M Wolfensberger; H Gudziol; A Temmel; C M Owen; H Seeber; E Pauli; T Hummel
Journal:  Eur Arch Otorhinolaryngol       Date:  2000       Impact factor: 2.503

8.  [Development of a grading scale for the Sino-Nasal Outcome Test-20 German Adapted Version (SNOT-20 GAV)].

Authors:  I Baumann; P K Plinkert; H De Maddalena
Journal:  HNO       Date:  2008-08       Impact factor: 1.284

Review 9.  Surgical therapy and olfactory function.

Authors:  P Bonfils; D Malinvaud; Y Soudry; M Devars du Maine; O Laccourreye
Journal:  B-ENT       Date:  2009       Impact factor: 0.082

10.  Concordant genotype of upper and lower airways P aeruginosa and S aureus isolates in cystic fibrosis.

Authors:  J G Mainz; L Naehrlich; M Schien; M Käding; I Schiller; S Mayr; G Schneider; B Wiedemann; L Wiehlmann; N Cramer; W Pfister; B C Kahl; J F Beck; B Tümmler
Journal:  Thorax       Date:  2009-03-11       Impact factor: 9.139

View more
  10 in total

1.  Validity and Reliability of a Novel Multimodal Questionnaire for the Assessment of Abdominal Symptoms in People with Cystic Fibrosis (CFAbd-Score).

Authors:  Anke Jaudszus; Elisa Zeman; Tatjana Jans; Elena Pfeifer; Harold Tabori; Christin Arnold; Ruth K Michl; Michael Lorenz; Natalie Beiersdorf; Jochen G Mainz
Journal:  Patient       Date:  2019-08       Impact factor: 3.883

Review 2.  Management of the upper airway in cystic fibrosis.

Authors:  Elisa A Illing; Bradford A Woodworth
Journal:  Curr Opin Pulm Med       Date:  2014-11       Impact factor: 3.155

3.  Olfaction before and after initiation of elexacaftor-tezacaftor-ivacaftor in a cystic fibrosis cohort.

Authors:  Daniel R Bacon; Amanda Stapleton; Jennifer L Goralski; Charles S Ebert; Brian D Thorp; Mehdi Nouraie; Amber D Shaffer; Brent A Senior; Stella E Lee; Anna C Zemke; Adam J Kimple
Journal:  Int Forum Allergy Rhinol       Date:  2021-10-28       Impact factor: 3.858

Review 4.  Medical interventions for chronic rhinosinusitis in cystic fibrosis.

Authors:  Tulasi Kota Karanth; Veena Kota Laxminarayan Kl Karanth; Bryan K Ward; Bradford A Woodworth; Laxminarayan Karanth
Journal:  Cochrane Database Syst Rev       Date:  2022-04-07

5.  Factors for severe outcomes following SARS-CoV-2 infection in people with cystic fibrosis in Europe.

Authors:  Andreas Jung; Annalisa Orenti; Fiona Dunlevy; Elina Aleksejeva; Egil Bakkeheim; Vladimir Bobrovnichy; Siobhán B Carr; Carla Colombo; Harriet Corvol; Rebecca Cosgriff; Géraldine Daneau; Deniz Dogru; Pavel Drevinek; Andrea Dugac Vukic; Isabelle Fajac; Alice Fox; Stojka Fustik; Vincent Gulmans; Satenik Harutyunyan; Elpis Hatziagorou; Irena Kasmi; Hana Kayserová; Elena Kondratyeva; Uroš Krivec; Halyna Makukh; Kestutis Malakauskas; Edward F McKone; Meir Mei-Zahav; Isabelle de Monestrol; Hanne Vebert Olesen; Rita Padoan; Tsitsino Parulava; Maria Dolores Pastor-Vivero; Luísa Pereira; Guergana Petrova; Andreas Pfleger; Liviu Pop; Jacqui G van Rens; Milan Rodic; Marc Schlesser; Valérie Storms; Oxana Turcu; Lukasz Woz Niacki; Panayiotis Yiallouros; Anna Zolin; Damian G Downey; Lutz Naehrlich
Journal:  ERJ Open Res       Date:  2021-12-27

6.  Medical and Surgical Advancements in the Management of Cystic Fibrosis Chronic Rhinosinusitis.

Authors:  Kiranya E Tipirneni; Bradford A Woodworth
Journal:  Curr Otorhinolaryngol Rep       Date:  2017-02-21

7.  Longitudinal improvement and stability of olfactory function in the evaluation of surgical management for chronic rhinosinusitis.

Authors:  Joshua M Levy; Jess C Mace; E Ritter Sansoni; Zachary M Soler; Timothy L Smith
Journal:  Int Forum Allergy Rhinol       Date:  2016-05-24       Impact factor: 3.858

Review 8.  Medical interventions for chronic rhinosinusitis in cystic fibrosis.

Authors:  Tulasi Kota Karanth; Veena Kota Laxminarayan Kl Karanth; Bryan K Ward; Bradford A Woodworth; Laxminarayan Karanth
Journal:  Cochrane Database Syst Rev       Date:  2019-10-23

9.  Olfactory dysfunction in people with cystic fibrosis with at least one copy of F508del.

Authors:  Daniel M Beswick; Stephen M Humphries; Connor D Balkissoon; Matthew Strand; Jessa E Miller; Aastha Khatiwada; Eszter K Vladar; David A Lynch; Jennifer L Taylor-Cousar
Journal:  Int Forum Allergy Rhinol       Date:  2022-01-14       Impact factor: 5.426

10.  TAS2R38 is a novel modifier gene in patients with cystic fibrosis.

Authors:  Alice Castaldo; Gustavo Cernera; Paola Iacotucci; Chiara Cimbalo; Monica Gelzo; Marika Comegna; Antonella Miriam Di Lullo; Antonella Tosco; Vincenzo Carnovale; Valeria Raia; Felice Amato
Journal:  Sci Rep       Date:  2020-04-02       Impact factor: 4.379

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.